8-K: Humana Reaffirms 2024 Earnings Guidance at Investor Meetings

Humana reaffirms its full-year 2024 earnings guidance of approximately $12.81 per share diluted EPS and $16.00 per share adjusted EPS during investor meetings.

Summary

• Humana's senior management is scheduled to meet with investors and analysts at various industry conferences and meetings between September 3, 2024, and September 30, 2024.
• During these meetings, the company intends to reaffirm its full-year 2024 guidance of approximately $12.81 in diluted earnings per common share (EPS).
• The company also reaffirmed its adjusted earnings per common share (Adjusted EPS) guidance of approximately $16.00 for the year ending December 31, 2024.
• This guidance is consistent with the guidance issued in Humana's press release dated July 31, 2024.
• Adjusted EPS is a non-GAAP financial measure that management uses to assess the company's core operating performance.
• The company provided a reconciliation of GAAP EPS to Adjusted EPS, including adjustments for amortization of intangibles, put/call valuation adjustments, the impact of exiting the employer group commercial medical products business, value creation initiatives, and tax impacts.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company is reaffirming its guidance, which is a sign of stability and confidence. However, the document also includes a cautionary statement about risks and uncertainties, which prevents a higher score.

Positives

• Humana's reaffirmation of its earnings guidance provides stability and predictability for investors.
• The company's management is actively engaging with investors and analysts, which demonstrates transparency.
• The reconciliation of GAAP EPS to Adjusted EPS provides a clear understanding of the adjustments made to arrive at the non-GAAP measure.

Risks

• The document includes a cautionary statement that forward-looking statements are subject to risks, uncertainties, and assumptions.
• The company's performance is subject to risks outlined in their SEC filings.

Future Outlook

The company reaffirms its full-year 2024 earnings guidance, indicating a consistent outlook for the remainder of the year.

Management Comments

• Management believes that Adjusted EPS, when presented with GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the company's core operating performance over time.
• Management uses Adjusted EPS as a consistent and uniform indicator of the company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation.

Industry Context

This announcement is typical for companies that engage with investors and analysts, providing updates on their financial outlook and performance. Reaffirming guidance is a common practice to maintain investor confidence.

Comparison to Industry Standards

• It is common for healthcare companies like Humana to provide both GAAP and non-GAAP earnings measures to give investors a more complete picture of their financial performance.
• Many companies in the healthcare sector, such as UnitedHealth Group (UNH) and CVS Health (CVS), also provide adjusted earnings figures, making Humana's approach consistent with industry practices.
• The specific adjustments made by Humana, such as for amortization of intangibles and business exits, are typical for companies undergoing strategic changes or acquisitions.

Stakeholder Impact

• Shareholders will likely view the reaffirmed guidance positively, as it provides clarity on the company's expected financial performance.
• Analysts will use this information to update their models and recommendations.
• The company's employees may see this as a sign of stability and continued operations.

Next Steps

• Humana's management will continue to meet with investors and analysts between September 3, 2024, and September 30, 2024.
• The company will likely provide further updates on its financial performance in future reports.

Key Dates

Keywords

earnings guidance, EPS, Adjusted EPS, investor meetings, financial performance, non-GAAP, Humana